EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, Mirati Therapeutics, PRTA, ARVN, GLPG, and represent 52.84% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: ARGX (+$115M), Mirati Therapeutics (+$97M), SRPT (+$80M), JAZZ (+$79M), ARVN (+$52M), TNGX (+$46M), IMNM (+$42M), PHVS (+$25M), NGNE (+$25M), VERV (+$17M).
- Started 10 new stock positions in ITOS, IMNM, SRPT, ATRA, PHVS, TYRA, ARGX, VERV, PMVP, NGNE.
- Reduced shares in these 10 stocks: RVMD (-$157M), SWTX (-$80M), MORF (-$37M), RLAY (-$35M), APLS (-$28M), SLRN (-$14M), ALLO (-$14M), DCPH (-$13M), PRME (-$5.7M), PHAT.
- Sold out of its positions in SLRN, ALLO, DCPH, PRLD, PRME, RLAY, SWTX, TPST.
- EcoR1 Capital was a net buyer of stock by $239M.
- EcoR1 Capital has $3.9B in assets under management (AUM), dropping by 29.91%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 51 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 17.4 | $669M | -3% | 11M | 59.86 |
|
| Mirati Therapeutics | 11.3 | $435M | +28% | 7.4M | 58.75 |
|
| Prothena Corp SHS (PRTA) | 10.9 | $421M | 12M | 36.34 |
|
|
| Arvinas Ord (ARVN) | 7.2 | $277M | +23% | 6.7M | 41.16 |
|
| Galapagos Nv Spon Adr (GLPG) | 6.1 | $234M | 5.8M | 40.65 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 4.9 | $188M | 6.0M | 31.31 |
|
|
| Anaptysbio Inc Common (ANAB) | 4.2 | $161M | 7.5M | 21.42 |
|
|
| Zymeworks Del (ZYME) | 3.6 | $140M | 13M | 10.39 |
|
|
| Tango Therapeutics (TNGX) | 3.4 | $132M | +52% | 13M | 9.90 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.2 | $125M | +175% | 1.0M | 123.00 |
|
| Argenx Se Sponsored Adr (ARGX) | 3.0 | $115M | NEW | 301k | 380.43 |
|
| Xencor (XNCR) | 2.9 | $112M | 5.3M | 21.23 |
|
|
| Kura Oncology (KURA) | 2.2 | $84M | 5.8M | 14.38 |
|
|
| Sarepta Therapeutics (SRPT) | 2.1 | $80M | NEW | 833k | 96.43 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.9 | $72M | +31% | 2.0M | 35.58 |
|
| Mersana Therapeutics (MRSN) | 1.2 | $45M | 19M | 2.32 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.2 | $45M | 5.6M | 7.96 |
|
|
| Immunome (IMNM) | 1.1 | $42M | NEW | 3.9M | 10.70 |
|
| Edgewise Therapeutics (EWTX) | 1.0 | $38M | 3.5M | 10.94 |
|
|
| Neumora Therapeutics (NMRA) | 0.9 | $35M | 2.1M | 17.05 |
|
|
| Third Harmonic Bio (THRD) | 0.9 | $35M | +6% | 3.2M | 10.97 |
|
| Voyager Therapeutics (VYGR) | 0.8 | $33M | 3.9M | 8.44 |
|
|
| Alector (ALEC) | 0.8 | $32M | 4.1M | 7.98 |
|
|
| Oric Pharmaceuticals (ORIC) | 0.8 | $31M | 3.4M | 9.20 |
|
|
| Tscan Therapeutics (TCRX) | 0.8 | $29M | 5.0M | 5.83 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.8 | $29M | 19M | 1.51 |
|
|
| Pharvaris N V (PHVS) | 0.7 | $25M | NEW | 900k | 28.05 |
|
| Neurogene Com Added (NGNE) | 0.6 | $25M | NEW | 1.3M | 19.38 |
|
| Graphite Bio | 0.6 | $22M | 8.5M | 2.62 |
|
|
| Atea Pharmaceuticals (AVIR) | 0.6 | $21M | 7.0M | 3.05 |
|
|
| Ovid Therapeutics (OVID) | 0.5 | $20M | 6.1M | 3.22 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.5 | $19M | +343% | 887k | 21.52 |
|
| Verve Therapeutics (VERV) | 0.5 | $17M | NEW | 1.3M | 13.94 |
|
| Iteos Therapeutics (ITOS) | 0.3 | $12M | NEW | 1.1M | 10.95 |
|
| Gossamer Bio (GOSS) | 0.2 | $8.4M | 9.2M | 0.91 |
|
|
| Morphic Hldg (MORF) | 0.2 | $6.1M | -85% | 211k | 28.88 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $5.9M | 3.0M | 1.98 |
|
|
| Atara Biotherapeutics (ATRA) | 0.1 | $5.2M | NEW | 10M | 0.51 |
|
| Aligos Therapeutics (ALGS) | 0.1 | $4.2M | +61% | 6.4M | 0.66 |
|
| Revolution Medicines (RVMD) | 0.1 | $3.8M | -97% | 133k | 28.68 |
|
| Hookipa Pharma Inc equity (HOOK) | 0.1 | $3.7M | 4.6M | 0.81 |
|
|
| Generation Bio (GBIO) | 0.1 | $3.4M | 2.0M | 1.65 |
|
|
| Ngm Biopharmaceuticals (NGM) | 0.1 | $2.0M | -62% | 2.4M | 0.86 |
|
| Allakos (ALLK) | 0.1 | $2.0M | 749k | 2.73 |
|
|
| Tyra Biosciences (TYRA) | 0.0 | $1.9M | NEW | 137k | 13.85 |
|
| Phathom Pharmaceuticals (PHAT) | 0.0 | $1.8M | -71% | 199k | 9.13 |
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $1.8M | NEW | 567k | 3.10 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $1.5M | 963k | 1.51 |
|
|
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.0 | $745k | 67k | 11.17 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $627k | 67k | 9.40 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $50k | 100k | 0.50 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022
- EcoR1 Capital 2021 Q3 restated filed Nov. 22, 2021
- EcoR1 Capital 2021 Q3 filed Nov. 15, 2021
- EcoR1 Capital 2021 Q2 filed Aug. 16, 2021
- EcoR1 Capital 2021 Q1 filed May 17, 2021
- EcoR1 Capital 2020 Q4 filed Feb. 16, 2021
- EcoR1 Capital 2020 Q3 filed Nov. 16, 2020
- EcoR1 Capital 2020 Q2 filed Aug. 14, 2020